As political scrutiny mounts, Eli Lilly divulges new insulin pricing data

Eli Lilly says the net price for its most popular insulin, insulin lispro recombinant (Humalog) fell to an average of $135 a patient a month in 2018 after discounts and rebates, from $147 in 2014. During the same period, the product's average list price rose 51.9% to $594 per patient monthly.

Eli Lilly says the net price for its most popular insulin, insulin lispro recombinant (Humalog) fell to an average of $135 a patient a month in 2018 after discounts and rebates, from $147 in 2014. During the same period, the product's average list price rose 51.9% to $594 per patient monthly. Lilly says the monthly per-patient prices were based on average use of insulin lispro recombinant if taken as prescribed. This amounts to about two vials or more than six pen injectors, though actual utilization may vary by patient. The rising cost of diabetes treatments has figured prominently in broader scrutiny of drug prices, and diabetes drugmakers like Lilly are facing criticism from patients, doctors, and lawmakers. In response to the pressure over insulin pricing, Lilly has begun taking steps, including announcing earlier this month it would start selling a generic version of insulin lispro recombinant at one-half the list price of the brand-name drug.